- Home
- BNS vs REGN Comparison
BNS vs REGN Comparison
Compare BNS & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNS
- REGN
- Stock Information
- Founded
- BNS 1832
- REGN 1988
- Country
- BNS Canada
- REGN United States
- Employees
- BNS N/A
- REGN N/A
- Industry
- BNS
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- BNS
- REGN Health Care
- Exchange
- BNS Nasdaq
- REGN Nasdaq
- Market Cap
- BNS 68.3B
- REGN 59.5B
- IPO Year
- BNS N/A
- REGN 1991
- Fundamental
- Price
- BNS $62.46
- REGN $577.95
- Analyst Decision
- BNS Hold
- REGN Buy
- Analyst Count
- BNS 2
- REGN 23
- Target Price
- BNS $80.00
- REGN $794.83
- AVG Volume (30 Days)
- BNS 1.7M
- REGN 988.2K
- Earning Date
- BNS 08-26-2025
- REGN 10-30-2025
- Dividend Yield
- BNS 4.91%
- REGN 0.61%
- EPS Growth
- BNS N/A
- REGN 5.03
- EPS
- BNS 3.78
- REGN 39.67
- Revenue
- BNS $22,903,284,079.00
- REGN $14,214,200,000.00
- Revenue This Year
- BNS $27.13
- REGN N/A
- Revenue Next Year
- BNS $3.31
- REGN $4.97
- P/E Ratio
- BNS $16.06
- REGN $14.64
- Revenue Growth
- BNS 7.43
- REGN 5.38
- 52 Week Low
- BNS $44.09
- REGN $476.49
- 52 Week High
- BNS $62.69
- REGN $1,210.97
- Technical
- Relative Strength Index (RSI)
- BNS 86.45
- REGN 54.04
- Support Level
- BNS $56.54
- REGN $575.04
- Resistance Level
- BNS $57.70
- REGN $597.02
- Average True Range (ATR)
- BNS 0.66
- REGN 15.97
- MACD
- BNS 0.62
- REGN -0.05
- Stochastic Oscillator
- BNS 96.49
- REGN 50.95
About BNS Bank Nova Scotia Halifax Pfd 3
Bank of Nova Scotia is a global financial services provider with over CAD 1.4 trillion in assets. The bank has four major business segments: Canadian banking, international banking, global wealth management, and global banking and markets. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in the Latin America region.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).